Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/ 3 Trial

NCT06282588 is registered in ClinicalTrials.gov with Cancer Research Antwerp as lead sponsor.

NCT NCT06282588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/ 3 Trial
Lead sponsor
Cancer Research Antwerp
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 13, 2023
Completion date
December 31, 2030
Enrollment
493 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer